Global Large And Small-scale Bioprocessing Market Size Likely to Grow at a CAGR of 11.5% By 2035

Market Size and Growth

The market size of the global large and small-scale bioprocessing will be estimated at USD 93.4 billion in 2025 and is expected to grow between USD 104.1 billion in 2026 and about USD 277.4 billion by 2035 with a current CAGR of 11.5% during the period of 2026 to 2035.

Large And Small-scale Bioprocessing Market Revenue and Trends

Bioprocessing, large or small, always involves microorganisms or their parts or metabolites in controlled biological systems such as living cells, microorganisms, or enzymes, etc., for the manufacture of biopharmaceuticals, vaccines, therapeutic proteins, enzymes, and other types of bio-based products in different production volumes. Small-scale bioprocessing is used mostly in R&D, process optimization, pilot studies, and early-stage clinical manufacturing where the main factors for testing and refining processes are flexibility, speed, and precise control. The transition to personalized medicine and targeted therapies has resulted in the demand for manufacturing solutions that are flexible and scalable, able to connect small-scale innovation with large-scale production. Additionally, the provision of regulatory support, the rise in investments in biomanufacturing infrastructure, and the expansion of biopharmaceutical production – especially in the Asia Pacific region – are significantly contributing to the large and small-scale bioprocessing market’s overall growth.

What are the Factors That Have a Significant Contribution to the Growth of the Large And Small-scale Bioprocessing market?

The rapid growth of the biopharmaceutical industry and the continuous evolution of technology are the main drivers behind the large and small bioprocessing market growth, which in turn has contributed significantly to the effective demand and supply of the biopharmaceuticals. The substantial surge in the consumption of biologics like monoclonal antibodies, vaccines, biosimilars, and cell and gene therapies, for instance, has brought about the necessity for their very viable and large-scale bioprocessing solutions that span both the developmental and commercial manufacturing stages. The U.S. biomanufacturing initiatives, therefore, are playing a crucial role in the expansion of the bioprocessing market by the very fact that they are driving the demand for a small-scale bioprocessing system for process optimization, pilot production, and clinical trials based on the commercialization of successful biologics. On the other hand, large-scale bioprocessing facilities are then further pushed to be developed through the very same process of commercialization of successful biologics.

Moreover, the bottlenecks caused by the introduction of new agreements are smoothed out through superior innovation and desirably less contamination risks and shorter time-to-market periods. Concurrently with these advancements, there are the positive regulatory environments, government funding, and support for domestic biomanufacturing that are the main driving forces of the global infrastructure expansion. The shift toward personalized medicine has also been the increasing focus, which combined with the expansion of contract development and manufacturing organizations (CDMOs) and growing biopharmaceutical activity in the emerging regions, is a key factor that supports the continuous growing of the large and small-scale bioprocessing market and thus makes it a central factor together with others, in the uninterrupted growth of the market.

Segment Insight

By Product Type

The bioreactors/fermenters segment is expected to hold the largest market share in 2025. The increase is attributed to the fact that they are at the core of upstream biomanufacturing processes. The role of bioreactors and fermenters is crucial as they provide the medium to grow cells and microorganisms for the manufacture of biologics, vaccines, recombinant proteins, enzymes, and cell and gene therapies. Biopharmaceutical pipeline expansion and the increasing number of drugs moving from clinical trials to marketing are the two main factors driving the demand for small bioreactors in research, process development, and pilot studies, as well as for large fermenters that are used in high-volume commercial production, and this demand is being significantly increased.

By Application

The biopharmaceuticals segment dominates the market over the projected period. The growth is majorly influenced by the commercial victory of biologics and biosimilars for clinical application in the present situation. Besides, the firms are taking steps to increase their manufacturing capabilities for biopharmaceutical development, which will likely result in substantial expansion of the market.

Regional Insights

The large and small-scale bioprocessing market has been dominated by North America. The superiority of the region in terms of revenue generation is due to its concentrating on high-tech research and development in biomanufacturing. For example, in June 2024, Ecolab Life Sciences along with Repligen Corporation introduced the DurA Cycle protein A chromatography resin in the U.S., which allows large-scale monoclonal antibody production at a lower cost and with a higher purity level. The growing demand for biologics and cell therapies, in addition to the significant number of bio-manufacturing plants located in this area, has also played a part in making this market segment so large.

Besides, the Asia Pacific market has the highest rate of growth in the large and small-scale bioprocessing market. The government’s efforts in the region’s economic development have directly influenced the healthcare sector and investors’ interest in it. As an example, MilliporeSigma, a division of Merck KGaA, invested in a bioprocessing production facility at Daejeon, South Korea, which is primarily aimed at supporting the development and manufacture of biologics, conducting clinical trials, and holding commercial production in April 2024.

Report Scope

Recent Developments

• In March 2023, Sartorius Stedim Biotech, the major global collaborator with the biopharmaceutical industry, has publicly declared a deal to buy Polyplus at the price of around 2.4 billion euros from investors, among whom are ARCHIMED and Warburg Pincus affiliated WP GG Holdings IV B.V. (Source: https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-to-acquire-polyplus-1410678)

List of the prominent players in the Large And Small-scale Bioprocessing Market:

• CESCO BIOENGINEERING CO. LTD
• ExcellGene SA
• Hoffmann-La Roche Ltd
• Corning Inc.
• Sartorius AG
• Lonza
• Merck KGaA
• Bio-Process Group
• BPC Instruments AB
• Eppendorf AG
• Getinge AB
• PBS Biotech Inc.
• Bio-Synthesis Inc.
• Meissner Filtration Products Inc.
• Entegris
• KUHNER AG
• Saint-Gobain
• Thermo Fisher Scientific Inc.
• Repligen Corporation
• Avantor Inc
• CerCell A/S
• Univercells Technologies
• Distek Inc.
• Danaher (Cytiva)
• Others

The Large And Small-scale Bioprocessing Market is segmented as follows:

By Scale

• Small Scale (Less Than 50,000 Liter)
• Industrial Scale (Over 50,000 Liter)

By Product

• Bioreactors/Fermenters
• Filtration Assemblies
• Cell Culture Products
• Bags & Containers
• Bioreactors Accessories
• Others

By Workflow

• Upstream Processing
• Downstream Processing
• Fermentation

By Application

• Biopharmaceuticals
• Environmental Aids
• Specialty Industrial Chemicals

By Use Type

• Multi-Use
• Single-Use

By Mode

• In-house
• Outsourced

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America